CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

ESPR is no longer listed: the SEC shows no trading symbol for it and it has no recent price, usually after an acquisition. CatalystAlert no longer tracks its catalysts.

Esperion Therapeutics, Inc.

ESPR
$811MSmall Cap

Next catalyst

No upcoming catalyst in our data

No upcoming FDA decision, filing or trial readout is on file for ESPR. That does not mean none is planned.

Get an email about ESPR's next catalysts

Track Esperion Therapeutics (ESPR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Catalyst Timeline

0 upcoming, 0 past

No catalysts found.

How ESPR's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsPharmaceuticalπŸ‡ΊπŸ‡ΈNorth AmericaANN ARBOR304 employees

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Website
Drug Pipeline

Frequently asked questions

What is in Esperion Therapeutics, Inc.'s drug pipeline?β†’

CatalystAlert tracks 4 drug candidates in Esperion Therapeutics, Inc.'s (ESPR) pipeline across Phase 3, Phase 2. Its lead program is Bempedoic Acid (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Esperion Therapeutics, Inc.'s next FDA catalyst?β†’

CatalystAlert tracks every upcoming catalyst for Esperion Therapeutics, Inc. (ESPR) β€” PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β€” each confidence-rated as confirmed, estimated or AI-detected.

How do I track ESPR biotech catalysts?β†’

Add ESPR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Esperion Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply